NCT03434353 - Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

January 20, 2020

Study Completion Date

January 26, 2021

Conditions

Chronic Hepatitis B

Interventions

DRUG

Inarigivir Soproxil

Administered orally once daily one hour before or one hour after a meal

DRUG

TAF

Administered orally once daily with food

Trial Locations (13)

Inje University Ilsan Paik Hospital, Ilsan

Keimyung University Dongsan Medical Center, Daegu

Kyungpook National University Hospital, Daegu

Alice Ho Miu Ling Nethersole Hospital, Hong Kong

Prince Margaret Hospital, Hong Kong

Prince of Wales Hospital-HK, Hong Kong

Korea University Ansan Hospital, Ansan

Severance Hospital, Yonsei University Health System, Seoul

Asan Medical Center, Seoul

Gangnam Severance Hospital, Yonsei University Health System, Seoul

Catholic University of Korea, Seoul Saint Mary's Hospital, Seoul

SMG-SNU Boramae Medical Center, Seoul

Korea University Guro Hospital, Seoul